Patient perceptions of treatment-free remission in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Patient perceptions of treatment-free remission in chronic myeloid leukemia

Published:2017-06-15 Issue:2 Volume:59 Page:406-415
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Villemagne Sanchez Lucia A.¹²,O’Callaghan Clare¹²³,Gough Karla¹²,Hall Karen⁴,Kashima Yoshihisa¹²,Seymour John F.¹⁵,Schofield Penelope²⁶,Ross David M.⁴⁷^ORCID

Affiliation:

1. Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne, Melbourne, VIC, Australia;

2. Department of Cancer Experience Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;

3. Department of Medicine, St Vincent’s Hospital and Institute, Cabrini Health Australia, Melbourne, VIC, Australia;

4. Haematology Directorate, SA Pathology, Flinders University and Medical Centre, Adelaide, SA, Australia;

5. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;

6. Department of Psychological Sciences, Swinburne University, Melbourne, VIC, Australia;

7. School of Medicine, University of Adelaide, Adelaide, SA, Australia

Funder

Novartis Pharmaceuticals

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1337114

Reference34 articles.

1. Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century

2. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

3. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

4. BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria

5. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF;Leukemia;2024-03-12

2. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon‐alpha;British Journal of Haematology;2023-07-22

3. Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients;Patient Preference and Adherence;2022-10

4. Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success;American Journal of Hematology;2022-04-12

5. Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools;Targeted Oncology;2021-10-18